| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.10. | Stimcell Energetics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| STIMCELL ENERGETICS Aktie jetzt für 0€ handeln | |||||
| 08.09. | Stimcell Energetics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | StimCell Energetics hires Stonegate for capital raising | 2 | Investing.com | ||
| 08.09. | StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions | 446 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging... ► Artikel lesen | |
| 31.08. | Stimcell Energetics Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 15.05. | Stonegate, Inc.: Stonegate Initiates Coverage on StimCell Energetics Inc. (STME) | 464 | Newsfile | Dallas, Texas--(Newsfile Corp. - May 15, 2026) - StimCell Energetics Inc. (OTCQB: STME): Stonegate Initiates Coverage on StimCell Energetics Inc. (OTCQB: STME). StimCell is a single-product company... ► Artikel lesen | |
| 19.03. | StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach | 861 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and... ► Artikel lesen | |
| 02.12.25 | StimCell Energetics Inc. Announces Study into eBalance Device's Impact on Neuronal Mitochondrial Function | 570 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,067 | 0,00 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| FAMICORD | 2,360 | -3,67 % | EQS-Adhoc: FamiCord AG: FamiCord beschließt Bezugspreis und Anzahl neuer Aktien für beabsichtigte Bezugsrechtskapitalerhöhung | EQS-Ad-hoc: FamiCord AG / Schlagwort(e): Kapitalmaßnahmen / Kapitalerhöhung
FamiCord AG: FamiCord beschließt Bezugspreis und Anzahl neuer Aktien für beabsichtigte Bezugsrechtskapitalerhöhung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,040 | -3,32 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| CERENOME | 0,508 | -12,41 % | Cerenome names Ron Andrews as chief business officer | ||
| MEDICLIN | 5,250 | -0,94 % | EQS-News: MEDICLIN AG: MEDICLIN setzt stabile Geschäftsentwicklung fort | EQS-News: MEDICLIN AG
/ Schlagwort(e): 9-Monatszahlen/Sonstiges
MEDICLIN setzt stabile Geschäftsentwicklung fort
05.11.2026 / 14:46 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,950 | +1,04 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax | Total revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| VERU | 2,140 | +0,94 % | Veru executive to present obesity drug data at industry conference | ||
| LIFEWARD | 5,840 | +0,52 % | Lifeward Ltd. - 8-K, Current Report | ||
| LIGHT AI | 0,025 | 0,00 % | Light AI Announces Resignation of Director and Officer | ||
| LIFESTANCE HEALTH GROUP | 14,550 | -0,07 % | LifeStance Health Prices Secondary Public Offering Of 45 Mln Shares At $13.12/Shr | ||
| GENEDX | 54,93 | +0,18 % | Why GeneDx Holdings Stock Just Dropped 16.6% | ||
| BRIGHTSPRING HEALTH SERVICES | 72,51 | +0,03 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| BILLIONTOONE | 112,12 | 0,00 % | BTIG reiterates Buy on BillionToOne stock, keeps $130 target |